Created at	Source	Raw Value	Validated value
June 2, 2023, 8 p.m.	usa	Phase II;Phase I: Occurrence of DLTs in all patients during the study treatment, until 21 days after cell infusion and the MTD	Phase II;Phase I: Occurrence of DLTs in all patients during the study treatment, until 21 days after cell infusion and the MTD
Oct. 26, 2020, 11:31 p.m.	usa	Occurrence of DLTs in all patients during the study treatment, until 21 days after cell infusion and the MTD	Occurrence of DLTs in all patients during the study treatment, until 21 days after cell infusion and the MTD